RxDoctor Payments Data

Sylvia Mohen, MD

Neurology · New York, NYNPI 1962790907

Payments from drug & device makers

$35,599in general payments, 2019–2025

Across 1,959 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • Teva Pharmaceuticals USA, Inc.$2K
  • UCB, Inc.$2K
  • Pfizer$2K
  • Harmony Biosciences LLC$1K
  • SK Life Science, Inc.$1K
  • plus $19K from 54 others

What the payments were for

  • Speaking & faculty fees$190%
  • Food & beverage$35,01798%
  • Education$5622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)433$7,683
Teva Pharmaceuticals USA, Inc.149$2,242
UCB, Inc.111$2,105
Pfizer118$1,923
Harmony Biosciences LLC60$1,385
SK Life Science, Inc.77$1,297
Lilly USA, LLC76$1,205
Amneal Pharmaceuticals LLC62$1,175
MDD US Operations, LLC37$1,095
Lundbeck LLC79$1,057
Eisai Inc.56$958
Neurelis, Inc.41$912
Amgen(2 entities)36$854
Biogen50$844
Biohaven Pharmaceuticals, Inc.45$819
Biohaven Pharmaceutical Holding Company Ltd.49$704
Bausch Health US, LLC38$584
Takeda Pharmaceuticals U.S.A., Inc.31$533
Merz Pharmaceuticals, LLC23$521
Sunovion Pharmaceuticals Inc.21$431
Avanir Pharmaceuticals, Inc.27$422
Abbott14$403
Supernus Pharmaceuticals, Inc.36$393
Novartis18$360
TG Therapeutics, Inc.15$351
Kyowa Kirin, Inc.16$325
Axsome Therapeutics, Inc.14$321
Ipsen Biopharmaceuticals, Inc12$269
Currax Pharmaceuticals LLC16$255
Almatica Pharma LLC12$238
Zyla Life Sciences, Inc.13$223
Boston Scientific7$217
Catalyst Pharmaceuticals, Inc.9$181
Corium, LLC11$180
Neurocrine Biosciences, Inc.7$162
GE HealthCare9$160
Sanofi7$152
AstraZeneca8$144
Idorsia Pharmaceuticals US Inc7$139
Upsher-smith Laboratories LLC7$136
Sumitomo Pharma America, Inc.6$128
Assertio Therapeutics, Inc.8$128
Scilex Pharmaceuticals Inc.6$125
Argenx US, Inc.4$120
Medtronic4$120
Johnson & Johnson(3 entities)5$111
Grifols USA, LLC4$95
Revance Therapeutics, Inc.3$94
Otsuka America Pharmaceutical, Inc.4$92
EMD Serono, Inc.6$92
GSK4$88
Mallinckrodt Hospital Products Inc.2$88
Bristol Myers Squibb5$88
Vertical Pharmaceuticals, LLC4$66
Azurity Pharmaceuticals, Inc.3$66
Jazz Pharmaceuticals Inc.3$64
Acadia Pharmaceuticals Inc3$59
Tonix Medicines, Inc.3$56
Greenwich Biosciences, Inc.3$54
Brainsway USA Inc1$48

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,599 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$431,498
Medicare patients
244
Services billed
36,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate21$33,216
NuedextaDextromethorphan Hbr/Quinidine15$22,803
Aimovig AutoinjectorErenumab-Aooe25$18,347
QuliptaAtogepant13$14,284
ReyvowLasmiditan Succinate15$11,180
Emgality PenGalcanezumab-Gnlm12$8,528
Gabapentin96$1,560
Memantine Hcl ErMemantine Hcl37$1,285
Oxcarbazepine13$1,279
Tizanidine Hcl30$861
Escitalopram Oxalate88$791
Memantine Hcl24$606
Clonazepam17$449
Modafinil11$431
AmantadineAmantadine Hcl12$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$1,923$33,21621 claims
Avanir Pharmaceuticals, Inc.Nuedexta$422$22,80315 claims
AbbVieQulipta$7,683$14,28413 claims
Lilly USA, LLCReyvow$1,205$11,18015 claims
Upsher-smith Laboratories LLCTopiramate$136$6611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →